These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 16109053)

  • 21. The biggest bang for the buck or bigger bucks for the bang: the fallacy of the cost-effectiveness threshold.
    Birch S; Gafni A
    J Health Serv Res Policy; 2006 Jan; 11(1):46-51. PubMed ID: 16378532
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Moving research into practice: A decision framework for integrating home telehealth into chronic illness care.
    Hebert MA; Korabek B; Scott RE
    Int J Med Inform; 2006 Dec; 75(12):786-94. PubMed ID: 16872892
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Economic evaluation of early intervention services.
    McCrone P; Knapp M
    Br J Psychiatry Suppl; 2007 Dec; 51():s19-22. PubMed ID: 18055933
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-of-illness analysis. What room in health economics?
    Tarricone R
    Health Policy; 2006 Jun; 77(1):51-63. PubMed ID: 16139925
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Economic burden of transformed migraine: results from the American Migraine Prevalence and Prevention (AMPP) Study.
    Munakata J; Hazard E; Serrano D; Klingman D; Rupnow MF; Tierce J; Reed M; Lipton RB
    Headache; 2009 Apr; 49(4):498-508. PubMed ID: 19245386
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Measuring the impact of headache in children: a critical review of the literature.
    Kernick D; Campbell J
    Cephalalgia; 2009 Jan; 29(1):3-16. PubMed ID: 18798844
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Understanding economic outcomes in critical care.
    Kahn JM
    Curr Opin Crit Care; 2006 Oct; 12(5):399-404. PubMed ID: 16943716
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Health economic decision making in Europe--a new priority for breast cancer advocacy.
    Knox S
    Breast; 2009 Apr; 18(2):71-2. PubMed ID: 19380086
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Economic evaluation for ophthalmologists.
    Kuper H; Jofre-Bonet M; Gilbert C
    Ophthalmic Epidemiol; 2006 Dec; 13(6):393-401. PubMed ID: 17169853
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacoeconomics and macular degeneration.
    Brown GC; Brown MM; Brown H; Godshalk AN
    Curr Opin Ophthalmol; 2007 May; 18(3):206-11. PubMed ID: 17435427
    [TBL] [Abstract][Full Text] [Related]  

  • 31. American Society of Clinical Oncology guidance statement: the cost of cancer care.
    Meropol NJ; Schrag D; Smith TJ; Mulvey TM; Langdon RM; Blum D; Ubel PA; Schnipper LE;
    J Clin Oncol; 2009 Aug; 27(23):3868-74. PubMed ID: 19581533
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The pharmacoeconomics of acne treatment: where are we heading?
    Inglese MJ; Fleischer AB; Feldman SR; Balkrishnan R
    J Dermatolog Treat; 2008; 19(1):27-37. PubMed ID: 18273722
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-benefit, cost-effectiveness and cost-utility analyses of periodontitis prevention.
    Braegger U
    J Clin Periodontol; 2005; 32 Suppl 6():301-13. PubMed ID: 16128845
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Money matters: what to look for in an economic analysis.
    Dijksman LM; Poolman RW; Bhandari M; Goeree R; Tarride JE;
    Acta Orthop; 2008 Feb; 79(1):1-11. PubMed ID: 18283565
    [No Abstract]   [Full Text] [Related]  

  • 35. [Guidelines for health-economic evaluations in Austria].
    Walter E; Zehetmayr S
    Wien Med Wochenschr; 2006 Dec; 156(23-24):628-32. PubMed ID: 17211768
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimal search strategies for detecting cost and economic studies in EMBASE.
    McKinlay RJ; Wilczynski NL; Haynes RB;
    BMC Health Serv Res; 2006 Jun; 6():67. PubMed ID: 16756662
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Health economic evaluation of rehabilitation programmes in the "rehabilitation sciences" research funding programme in Germany].
    Krauth C; Hessel F; Klingelhöfer HE; Schweikert B; Hansmeier T; Wasem J
    Rehabilitation (Stuttg); 2005 Oct; 44(5):297-306. PubMed ID: 16208593
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of budget impact in drug reimbursement decisions.
    Cohen JP; Stolk E; Niezen M
    J Health Polit Policy Law; 2008 Apr; 33(2):225-47. PubMed ID: 18325899
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Economic evaluation in oral care. Methods and examples in restorative dentistry].
    De Graeve D; Van Tendeloo I
    Ned Tijdschr Tandheelkd; 2004 Jun; 111(6):213-9. PubMed ID: 15224440
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Economic costs of drug abuse: financial, cost of illness, and services.
    Cartwright WS
    J Subst Abuse Treat; 2008 Mar; 34(2):224-33. PubMed ID: 17596904
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.